• 1nhaler secured £2.2 million in follow-on funding led by Archangels, with support from Scottish Enterprise and BBB Investments.
• The Edinburgh-based drug delivery device developer makes a single-dose, predominantly cardboard inhaler that folds to the size of a credit card.
• Funding will advance 1nhaler Salbutamol into clinical testing to support a regulatory filing targeted for late 2027.
• Proceeds will also fund a manufacturing engineering study with Harro Höfliger to support commercial scale-up.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Archangel Investors Ltd published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.